Use of flow cytofliuorimeter for the development and analysis of therapeutic, diagnostic and research antibodies (Q3958271): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: add summary) |
(Changed an Item: Adding English translations) |
||||||||||||||
| Property / summary | |||||||||||||||
Every year, the population of Hungary is reduced by the population of a small settlement. For decades, atherosclerosis-related diseases have been the leading cause of death statistics for decades, despite scientific achievements and drug developments over the past 60 years. On the other hand, 25 % of the deaths caused by the disease come from cancers, which are increasingly aggressively attacking the younger population (approximately 70,000 people in our country are told that they have malignancies each year). Autoimmune diseases are predominantly chronic, resulting in the destruction of affected organs and cells. Around 6-7 % of the adult population is affected by this disease group, which means that around 400-500 000 patients with autoimmune diseases live in Hungary. While MEA therapy has been successfully used for more than a decade in the last two diseases, the development and administration of antibodies to cure atherosclerosis is expected within a few years. MEA can be said to be more targeted and effective in treating these diseases. In addition to therapeutic use, these types of reagents are used to an excellent extent both in diagnostics and in all aspects of life science research. We are planning to purchase a modern flow cytofluorimeter system — B53009 Beckman Coulter CytoFLEX System B3-R3-V2 and its accessories — CytoFLEX Plate loader (gross price 52,2 mHUF). The maintenance cost of the apparatus is low and is able to perform high throughput screening (HTS), i.e. analyses from a cell culture vessel with 96 measurement points. The apparatus is suitable for the determination of the proportion of different particles, cell types and the specific detection of individual cell surface and intracellular molecules. For this, MEAs are most often used. During the development and validation of the MEA, the HTS capability is particularly important, given that in many cases the number of samples can be up to several hundred, i.e. without this type of device, research and service operations at the focal point of the application cannot be carried out. Another outstanding advantage of the device compared to current devices is that it is equipped with three lasers. In practice, this means that 8-13 markers (“cell identifiers”) can be identified in a single tube instead of the 3-5 available so far, and the relatively minor but biologically important changes in gene expression can be detected. The latter allows us to analyse cell subpopulations that are difficult to detect or detect small gene expression. The device can measure from a minimum sample volume (from a microcentrifuge tube or 96-hole plate — up to 10 ul samples are sufficient), thus saving valuable sample and reagent. We emphasise that, according to our knowledge, with a multi-channel, HTS-type flow cytofluorimeter in the Central Hungary region only Richter Gedeon Zrt. is owned by Richter Gedeon Zrt., so we can say that the procurement of the instrument is of paramount importance for research and industrial connections in this direction. Senior educators-researchers working at the Department of Immunology of ELTE are internationally recognised experts of the antibody structure function, which is confirmed by a number of high-quality publications and winning applications. Our staff deals with the elements of (1) congenital immune response (complement, H-factor) with internationally recognised scientific standards: Anna Erdő MTA member, Zsuzsanna Bajtay, DSc, Mihály Józsi, PhD, Hungarian Academy of Sciences winners; with (2) Fc? receptors and signalling of immune cells: Gabriella Sármay, DSc, subcellular analysis of the relationship between (3) immune cells: Matkó János, DSc and (4) IgG FcRn mediated catabolism and homeostasis: Imre Kachkovics, DSc. The state-of-the-art of the device to be procured by the present tender (simultaneous marking of 8-13 markers, HTS and ease of operation) is an indispensable development for all these researches, because it would significantly enhance the efficiency of scientific research and thus the success of the national and international tender. Dr. Imre Kacskovics has been working closely with the Richter Gedeon Pharmaceutical Company since 2011 and provides R & D & I services for this project, and participates in a joint competition (VKSZ-12). The flow cytofluorimeter to be procured can provide opportunities for further R & D & I collaborations and services (see the related Richter Gedeon Statement of Intent in the Grant Statements), potentially creating new research jobs. The Department of Immunology strives to make industrial use of its scientific findings. In recent years, it has produced several patent applications for antibodies, two of which have been accepted at international level. One of the patents currently in ImmunoGenes Kft. (http://www.immunogenes.com/) and Kyow (English) | |||||||||||||||
| Property / summary: Every year, the population of Hungary is reduced by the population of a small settlement. For decades, atherosclerosis-related diseases have been the leading cause of death statistics for decades, despite scientific achievements and drug developments over the past 60 years. On the other hand, 25 % of the deaths caused by the disease come from cancers, which are increasingly aggressively attacking the younger population (approximately 70,000 people in our country are told that they have malignancies each year). Autoimmune diseases are predominantly chronic, resulting in the destruction of affected organs and cells. Around 6-7 % of the adult population is affected by this disease group, which means that around 400-500 000 patients with autoimmune diseases live in Hungary. While MEA therapy has been successfully used for more than a decade in the last two diseases, the development and administration of antibodies to cure atherosclerosis is expected within a few years. MEA can be said to be more targeted and effective in treating these diseases. In addition to therapeutic use, these types of reagents are used to an excellent extent both in diagnostics and in all aspects of life science research. We are planning to purchase a modern flow cytofluorimeter system — B53009 Beckman Coulter CytoFLEX System B3-R3-V2 and its accessories — CytoFLEX Plate loader (gross price 52,2 mHUF). The maintenance cost of the apparatus is low and is able to perform high throughput screening (HTS), i.e. analyses from a cell culture vessel with 96 measurement points. The apparatus is suitable for the determination of the proportion of different particles, cell types and the specific detection of individual cell surface and intracellular molecules. For this, MEAs are most often used. During the development and validation of the MEA, the HTS capability is particularly important, given that in many cases the number of samples can be up to several hundred, i.e. without this type of device, research and service operations at the focal point of the application cannot be carried out. Another outstanding advantage of the device compared to current devices is that it is equipped with three lasers. In practice, this means that 8-13 markers (“cell identifiers”) can be identified in a single tube instead of the 3-5 available so far, and the relatively minor but biologically important changes in gene expression can be detected. The latter allows us to analyse cell subpopulations that are difficult to detect or detect small gene expression. The device can measure from a minimum sample volume (from a microcentrifuge tube or 96-hole plate — up to 10 ul samples are sufficient), thus saving valuable sample and reagent. We emphasise that, according to our knowledge, with a multi-channel, HTS-type flow cytofluorimeter in the Central Hungary region only Richter Gedeon Zrt. is owned by Richter Gedeon Zrt., so we can say that the procurement of the instrument is of paramount importance for research and industrial connections in this direction. Senior educators-researchers working at the Department of Immunology of ELTE are internationally recognised experts of the antibody structure function, which is confirmed by a number of high-quality publications and winning applications. Our staff deals with the elements of (1) congenital immune response (complement, H-factor) with internationally recognised scientific standards: Anna Erdő MTA member, Zsuzsanna Bajtay, DSc, Mihály Józsi, PhD, Hungarian Academy of Sciences winners; with (2) Fc? receptors and signalling of immune cells: Gabriella Sármay, DSc, subcellular analysis of the relationship between (3) immune cells: Matkó János, DSc and (4) IgG FcRn mediated catabolism and homeostasis: Imre Kachkovics, DSc. The state-of-the-art of the device to be procured by the present tender (simultaneous marking of 8-13 markers, HTS and ease of operation) is an indispensable development for all these researches, because it would significantly enhance the efficiency of scientific research and thus the success of the national and international tender. Dr. Imre Kacskovics has been working closely with the Richter Gedeon Pharmaceutical Company since 2011 and provides R & D & I services for this project, and participates in a joint competition (VKSZ-12). The flow cytofluorimeter to be procured can provide opportunities for further R & D & I collaborations and services (see the related Richter Gedeon Statement of Intent in the Grant Statements), potentially creating new research jobs. The Department of Immunology strives to make industrial use of its scientific findings. In recent years, it has produced several patent applications for antibodies, two of which have been accepted at international level. One of the patents currently in ImmunoGenes Kft. (http://www.immunogenes.com/) and Kyow (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Every year, the population of Hungary is reduced by the population of a small settlement. For decades, atherosclerosis-related diseases have been the leading cause of death statistics for decades, despite scientific achievements and drug developments over the past 60 years. On the other hand, 25 % of the deaths caused by the disease come from cancers, which are increasingly aggressively attacking the younger population (approximately 70,000 people in our country are told that they have malignancies each year). Autoimmune diseases are predominantly chronic, resulting in the destruction of affected organs and cells. Around 6-7 % of the adult population is affected by this disease group, which means that around 400-500 000 patients with autoimmune diseases live in Hungary. While MEA therapy has been successfully used for more than a decade in the last two diseases, the development and administration of antibodies to cure atherosclerosis is expected within a few years. MEA can be said to be more targeted and effective in treating these diseases. In addition to therapeutic use, these types of reagents are used to an excellent extent both in diagnostics and in all aspects of life science research. We are planning to purchase a modern flow cytofluorimeter system — B53009 Beckman Coulter CytoFLEX System B3-R3-V2 and its accessories — CytoFLEX Plate loader (gross price 52,2 mHUF). The maintenance cost of the apparatus is low and is able to perform high throughput screening (HTS), i.e. analyses from a cell culture vessel with 96 measurement points. The apparatus is suitable for the determination of the proportion of different particles, cell types and the specific detection of individual cell surface and intracellular molecules. For this, MEAs are most often used. During the development and validation of the MEA, the HTS capability is particularly important, given that in many cases the number of samples can be up to several hundred, i.e. without this type of device, research and service operations at the focal point of the application cannot be carried out. Another outstanding advantage of the device compared to current devices is that it is equipped with three lasers. In practice, this means that 8-13 markers (“cell identifiers”) can be identified in a single tube instead of the 3-5 available so far, and the relatively minor but biologically important changes in gene expression can be detected. The latter allows us to analyse cell subpopulations that are difficult to detect or detect small gene expression. The device can measure from a minimum sample volume (from a microcentrifuge tube or 96-hole plate — up to 10 ul samples are sufficient), thus saving valuable sample and reagent. We emphasise that, according to our knowledge, with a multi-channel, HTS-type flow cytofluorimeter in the Central Hungary region only Richter Gedeon Zrt. is owned by Richter Gedeon Zrt., so we can say that the procurement of the instrument is of paramount importance for research and industrial connections in this direction. Senior educators-researchers working at the Department of Immunology of ELTE are internationally recognised experts of the antibody structure function, which is confirmed by a number of high-quality publications and winning applications. Our staff deals with the elements of (1) congenital immune response (complement, H-factor) with internationally recognised scientific standards: Anna Erdő MTA member, Zsuzsanna Bajtay, DSc, Mihály Józsi, PhD, Hungarian Academy of Sciences winners; with (2) Fc? receptors and signalling of immune cells: Gabriella Sármay, DSc, subcellular analysis of the relationship between (3) immune cells: Matkó János, DSc and (4) IgG FcRn mediated catabolism and homeostasis: Imre Kachkovics, DSc. The state-of-the-art of the device to be procured by the present tender (simultaneous marking of 8-13 markers, HTS and ease of operation) is an indispensable development for all these researches, because it would significantly enhance the efficiency of scientific research and thus the success of the national and international tender. Dr. Imre Kacskovics has been working closely with the Richter Gedeon Pharmaceutical Company since 2011 and provides R & D & I services for this project, and participates in a joint competition (VKSZ-12). The flow cytofluorimeter to be procured can provide opportunities for further R & D & I collaborations and services (see the related Richter Gedeon Statement of Intent in the Grant Statements), potentially creating new research jobs. The Department of Immunology strives to make industrial use of its scientific findings. In recent years, it has produced several patent applications for antibodies, two of which have been accepted at international level. One of the patents currently in ImmunoGenes Kft. (http://www.immunogenes.com/) and Kyow (English) / qualifier | |||||||||||||||
point in time: 9 February 2022
| |||||||||||||||
Revision as of 18:46, 9 February 2022
Project Q3958271 in Hungary
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Use of flow cytofliuorimeter for the development and analysis of therapeutic, diagnostic and research antibodies |
Project Q3958271 in Hungary |
Statements
54,954,274 forint
0 references
200,299.214 Euro
0.0027336256 Euro
15 December 2021
0 references
73,272,365.333 forint
0 references
74.999997 percent
0 references
9 June 2017
0 references
29 August 2020
0 references
EÖTVÖS LORÁND TUDOMÁNYEGYETEM
0 references
47°29'30.62"N, 18°58'44.15"E
0 references
Magyarország népessége minden évben egy kistelepülés lakosságának számával lesz kevesebb. Az elmúlt 60 év tudományos eredményei és gyógyszerfejlesztései ellenére évtizedek óta, világszerte az atherosclerosis okozta megbetegedések vezetik a haláloki statisztikákat. Másfelől, a betegség okozta halálozások 25 százaléka a daganatos megbetegedésekből származik, amelyek egyre agresszívebb módon mindinkább a fiatalabb populációt támadják meg (hazánkban évente megközelítőleg 70 000 emberrel közlik, hogy rosszindulatú daganata van). Az autoimmun betegségek döntően idült lefolyásúak, az érintett szervek, sejtek pusztulásával járnak. A felnőtt lakosság kb. 6-7 %-át érinti ez a betegségcsoport, ami tehát azt jelenti, hogy Magyarországon megközelítően mintegy 400-500 ezer autoimmun betegségben szenvedő beteg él. Míg az utóbbi két betegségben több mint egy évtizede alkalmazzák sikerrel a mEa terápiát, az atherosclerosis gyógyításához szükséges ellenanyagok kifejlesztése és alkalmazása néhány éven belül várható. Kijelenthető, hogy a mEa-kal célzottabban és hatékonyabban kezelhetők ezek a típusú betegségek. A terápiás felhasználás mellett az ilyen típusú reagensek úgy a diagnosztikában, mint az élettudományi kutatások minden vonatkozásában kimagasló mértékben használatosak. A pályázat kapcsán egy korszerű, sokcsatornás és nagyszámú mintaelemzésre képes áramlási citofluoriméter rendszert - B53009 Beckman Coulter CytoFLEX System B3-R3-V2-t és annak tartozékát CytoFLEX Plate loader- tervezünk beszerezni (bruttó ára 52,2 mHUF). A készülék fenntartási költsége alacsony és képes nagy áteresztőképességű elemzésekre (high throughput screening, HTS), azaz 96-mérőhelyes sejttenyésztő edényből elemzéseket végezni. A készülék alkalmas különböző részecskék, sejttípusok arányának meghatározására, ill. az egyes sejtfelszíni és intracelluláris molekulák specifikus detektálására. Ehhez leggyakrabban mEa-okat alkalmaznak. A mEa fejlesztése és validálása során a HTS képesség kiemelten fontos, tekintettel arra, hogy számos esetben a minták száma akár több-száz is lehet, azaz ilyen típusú készülék nélkül a pályázat fókuszpontjában álló kutatási és szolgáltatási műveletek nem végezhetők el. A készülék további kiemelkedő előnye a jelenlegi készülékekhez képest az, hogy három lézerrel szerelték fel. A gyakorlatban ez annyit jelent, hogy egyetlen csőben 8-13 markert („sejtazonosítót”) tudunk jelölni az eddig elérhető 3-5 helyett és a relatív kisebb mértékű, ám biológiailag fontos génkifejeződés változások is detektálhatóak. Ez utóbbi lehetővé teszi, hogy nehezen kimutatható sejt alpopulációkat elemezzünk, ill. kismértékű gén kifejeződést is detektáljunk. A készülék minimális mintamennyiségből is tud mérni (mikrocentrifuga csőből vagy 96-lyukú plate-ből - akár 10 ul minta elegendő), így értékes minta és reagens megtakarítás érhető el. Hangsúlyozzuk, hogy ilyen érzékenységű, sokcsatornás, HTS típusú áramlási citofluoriméterrel tudomásunk szerint a Közép-magyarországi régióban kizárólag a Richter Gedeon Zrt rendelkezik, így kijelenthetjük a műszer beszerzése ilyen irányú kutatásokra és ipari kapcsolatok kialakítására hiánypótló jelentőségű. Az ELTE Immunológiai Tanszékén dolgozó vezető oktatók-kutatók az ellenanyagok struktúra-funkció nemzetközileg elismert szakértői, amit számos magas színvonalú publikáció, ill. elnyert pályázat igazol. Munkatársaink nemzetközileg is elismert tudományos igényességgel foglalkoznak a (1) veleszületett immunválasz egyes elemeivel (komplement, H-faktor): Erdei Anna MTA rendes tag, Bajtay Zsuzsanna, DSc, Józsi Mihály, PhD, MTA Lendület nyertes; az (2) Fc?-receptorokkal és az immunsejtek szignalizációjával: Sármay Gabriella, DSc, az (3) immunsejtek egymás közötti kapcsolatának szubcelluláris elemzésével: Matkó János, DSc, valamint az (4) IgG FcRn mediált katabolizmusával és homeosztázisával: Kacskovics Imre, DSc. Mindezekhez a kutatásokhoz nélkülözhetetlen fejlesztést jelent a jelen pályázat révén beszerzendő készülék korszerűsége (8-13 marker egyidejű jelölése, HTS és könnyű kezelhetőség), mert jelentősen fokozná a tudományos kutatások hatásfokát és ezáltal a hazai és nemzetközi pályázati eredményességet. A jelen pályázat témavezetője, Dr. Kacskovics Imre 2011-től szorosan együttműködik a Richter Gedeon gyógyszergyárral és számára K+F+I szolgáltatásokat nyújt, ill. közös konzorciális pályázatban (VKSZ-12) vesz részt. A beszerzendő áramlási citofluoriméter lehetőséget adhat további K+F+I együttműködésekre, ill. szolgáltatások nyújtására (ld. a Támogató nyilatkozatokban szereplő kapcsolódó Richter Gedeon Szándéknyilatkozatot), aminek kapcsán potenciálisan új kutatói munkahelyeket tudnánk teremteni. Az Immunológiai Tanszék törekszik arra, hogy tudományos eredményeit iparilag is hasznosítsa. Az elmúlt években az ellenanyagokkal kapcsolatosan több szabadalmi bejelentést készített, amelyből két szabadalmat nemzetközi szinten is elfogadtak. Az egyik szabadalmat jelenleg ImmunoGenes Kft (http://www.immunogenes.com/) és a Kyow (Hungarian)
0 references
Every year, the population of Hungary is reduced by the population of a small settlement. For decades, atherosclerosis-related diseases have been the leading cause of death statistics for decades, despite scientific achievements and drug developments over the past 60 years. On the other hand, 25 % of the deaths caused by the disease come from cancers, which are increasingly aggressively attacking the younger population (approximately 70,000 people in our country are told that they have malignancies each year). Autoimmune diseases are predominantly chronic, resulting in the destruction of affected organs and cells. Around 6-7 % of the adult population is affected by this disease group, which means that around 400-500 000 patients with autoimmune diseases live in Hungary. While MEA therapy has been successfully used for more than a decade in the last two diseases, the development and administration of antibodies to cure atherosclerosis is expected within a few years. MEA can be said to be more targeted and effective in treating these diseases. In addition to therapeutic use, these types of reagents are used to an excellent extent both in diagnostics and in all aspects of life science research. We are planning to purchase a modern flow cytofluorimeter system — B53009 Beckman Coulter CytoFLEX System B3-R3-V2 and its accessories — CytoFLEX Plate loader (gross price 52,2 mHUF). The maintenance cost of the apparatus is low and is able to perform high throughput screening (HTS), i.e. analyses from a cell culture vessel with 96 measurement points. The apparatus is suitable for the determination of the proportion of different particles, cell types and the specific detection of individual cell surface and intracellular molecules. For this, MEAs are most often used. During the development and validation of the MEA, the HTS capability is particularly important, given that in many cases the number of samples can be up to several hundred, i.e. without this type of device, research and service operations at the focal point of the application cannot be carried out. Another outstanding advantage of the device compared to current devices is that it is equipped with three lasers. In practice, this means that 8-13 markers (“cell identifiers”) can be identified in a single tube instead of the 3-5 available so far, and the relatively minor but biologically important changes in gene expression can be detected. The latter allows us to analyse cell subpopulations that are difficult to detect or detect small gene expression. The device can measure from a minimum sample volume (from a microcentrifuge tube or 96-hole plate — up to 10 ul samples are sufficient), thus saving valuable sample and reagent. We emphasise that, according to our knowledge, with a multi-channel, HTS-type flow cytofluorimeter in the Central Hungary region only Richter Gedeon Zrt. is owned by Richter Gedeon Zrt., so we can say that the procurement of the instrument is of paramount importance for research and industrial connections in this direction. Senior educators-researchers working at the Department of Immunology of ELTE are internationally recognised experts of the antibody structure function, which is confirmed by a number of high-quality publications and winning applications. Our staff deals with the elements of (1) congenital immune response (complement, H-factor) with internationally recognised scientific standards: Anna Erdő MTA member, Zsuzsanna Bajtay, DSc, Mihály Józsi, PhD, Hungarian Academy of Sciences winners; with (2) Fc? receptors and signalling of immune cells: Gabriella Sármay, DSc, subcellular analysis of the relationship between (3) immune cells: Matkó János, DSc and (4) IgG FcRn mediated catabolism and homeostasis: Imre Kachkovics, DSc. The state-of-the-art of the device to be procured by the present tender (simultaneous marking of 8-13 markers, HTS and ease of operation) is an indispensable development for all these researches, because it would significantly enhance the efficiency of scientific research and thus the success of the national and international tender. Dr. Imre Kacskovics has been working closely with the Richter Gedeon Pharmaceutical Company since 2011 and provides R & D & I services for this project, and participates in a joint competition (VKSZ-12). The flow cytofluorimeter to be procured can provide opportunities for further R & D & I collaborations and services (see the related Richter Gedeon Statement of Intent in the Grant Statements), potentially creating new research jobs. The Department of Immunology strives to make industrial use of its scientific findings. In recent years, it has produced several patent applications for antibodies, two of which have been accepted at international level. One of the patents currently in ImmunoGenes Kft. (http://www.immunogenes.com/) and Kyow (English)
9 February 2022
0 references
Budapest, Budapest
0 references
Identifiers
VEKOP-2.3.3-15-2017-00021
0 references